Severe cutaneous ulcerations secondary to xylazine (tranq): A case series
Abstract
ED: emergency department IVDU: intravenous drug use UDS: urine drug screen INTRODUCTION Xylazine, commonly referred to by its street name ‘‘tranq’’, is a nonopioid veterinary tranquilizer increasingly found in the illicit drug supply. First detected in 2006, xylazine is now found as an adulterant in over 90% of illegal drug samples tested in Philadelphia and has been detected in the drug supply of 48 states nationwide. Between 2010 and 2020, drug overdose deaths involving illicit opioids containing xylazine have increased from 2% to 31% in Philadelphia. In 2019, xylazine was implicated in overdose deaths in 25 of 38 states that performed xylazine testing. Severe skin ulceration is a common complication of xylazine use. Herein, we report 6 cases of xylazine-associated skin ulcerations (Table I).
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.